Reference

1. Przemysbaw Baranowski, Bohena karolewicz, et al. Ophthalmic drug dosage forms: characterisation and research methods. Hindawi publishing corporation e scientific world journal volume 2014, article in 861904, 14 pages http://dx.doi.org/10.1155/2014/861904.
2.  Duaa j. Al-tamimi1, Afaq m. Ammoo, et al. Review article ophthalmic dosage forms kerabala journal of pharmaceutical science no (18) received (april-2020), accepted (april-2020) drjaafarjaber@yahoo.com.
3. Priti bokil1, Dr. Gajanan sanap2, et al. Published by international journal of advanced research in science, communication and technology Doi: 10.48175/568 page no 324 to 326.
4. Gan l, wang j, et al. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. Drug discovery. Pmid: 23092895 Doi: 10.1016/j.drudis.2012.10.005  today 2013; 18, page no 290-297.
5. Le Bourdais c, Scar l, et al. Ophthalmic drug delivery systems—recent advances pmid: 9537794 Doi: 10.1016/s1350-9462(97)00002-5. Prog. Retin. Eye res. 1998; 17, page no 33–58.
6. P. Pahuja, s. Arora, et al.  “Ocular drug delivery system: a reference to natural polymers,” expert opinion on drug delivery January 2022. Doi:10.1016/b978-0-323-85873-1.00005-8 , vol. 9, no. 7, page no 837–861, 2012.
7. R. Gaudana, j. Jwala, et al. “Recent perspectives in ocular drug delivery,” pharmaceutical research, http://dx.doi.org/10.1155/2014/861904 vol. 26, no. 5, page no 1197–1216, 2009.
8. P. Tangri and s. Khurana, et al. “Basics of ocular drug delivery systems,” international journal research in pharmaceutical and biomedical sciences,www.ijrpbsonline.com  vol. 2, no. 4, page no 1541–1552.
9. “The international pharmacopoeia,” 4th edition, 2013, http://apps.who.int/phint/en/p/about/.
10. Jitendra, p. K. Sharma, et al. “A new trend: ocular drug delivery system,” an international journal of pharmaceutical sciences, vol. 2, no. 3, page no 1–25, 2011.
11. M. Yamaguchi, S.-I Yasuda, et al. “formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluorinated,” international journal of pharmaceutics, https://doi.org/10.1016/j.ijpharm.2005.05.036 vol. 301, no. 1-2, page no 121–128, 2005.
12. Jurvanen t, Jurvanen k, et al. Prodrugs for improved ocular drug delivery. Advanced drug delivery reviews. Https://doi.org/10.1016/0169-409x(95)00107 . 1996;19(2) page no 203–224.
13. Rajasekaran a, Kumaran ksga, et al. A comparative review on conventional and advanced ocular drug delivery formulations. International journal of pharmtech research. 2010;2(1): page no 668–674.
14. K. S. Rathore and r. K. Nema, et al. “an insight into ophthalmic drug delivery system,” international journal of pharmaceutical sciences and drug research, https://doi.org/10.25004/ijpsdr.2009.010101 vol. 1, no. 1, page no 1–5, 2009.
15. Richard su¨verkru¨pa, * Sabine grunt Hala, et al. Michael distalmost the ophthalmic lyophilizate carrier system (olcs) European journal of pharmaceutics and biopharmaceutics 57 (2004) page no 269–277 www.elsevier.com/locate/ejpb
16. Christle le Boulais I, Liliane acer 1, et al. Ophthalmic drug delivery systems recent advances progress in retinal and eye research pmid: 9537794 Doi: 10.1016/s1350-9462(97)00002-5 vol. 17, no. 1, page no 33-58, 1998
17. M. H. Aburahma, A. A. Mahmoud, et al. “Biodegradable ocular inserts for sustained delivery of brimonidine tartrate: preparation and in vitro/in vivo evaluation,” asps pharm SciTech, pmid: 21979886 Doi: 10.1208/s12249-011-9701-3   vol.12, no. 4, page no 1335–1347, 2011.
18. G. Venkata Ratnam, S. Madhavi, et al. “Ocular drug delivery: an update review,” international journal of pharmacy and biological sciences, vol. 1, no. 4, page no 437–446, 2011 venkatgogusetti@gmail.com
19. Shivhare r, Pathak a, et al. An update review on novel advanced ocular drug delivery system. World journal of pharmacy and pharmaceutical sciences. 2012; vol.1, no.2, page no 545–568.www.wjpps.com
20. Maichuk yf. Ophthalmic drug inserts. Investigative ophthalmology. 1975; vol.14, no.2, page no 87–90. pmid: 1112643
21. Karthikeyan d, Bhowmik m, et al. The concept of ocular inserts as drug delivery systems: an overview. Asian journal of pharmaceutics. 2008; vol.2, no. 4, page no 192- 200. Https://doi.org/10.22377/ajp.v2i4.204.
22. Lloyd r. Applicants for pharmaceutically active agents, their preparation and use. U.k. intellectual property office, gb, 2097680 a, 19821110, 1982.
23. Diestel horst m, Krieg stein gk.et al. The ocular tolerability of a new ophthalmic drug delivery system (nods). International ophthalmology. 1994; vol.18, no.1, page no 1–4 .https://doi.org/10.1007/bf00919405
24. Moosa rm, Choonara ye, et al. A review of topically administered mini-tablets for drug delivery to the anterior segment of the eye. Journal of pharmacy and pharmacology. 2013; 66(4): Doi: 10.1111/jphp.12131. Pmid: 24635554. page no 490-506
25. Mortazavi sa, Jaffar Azar z, et al. Formulation and in-vitro evaluation of ocular ciprofloxacin-containing minitablets prepared with different combinations of carbopol 974p and various cellulose derivatives. Iranian journal of pharmaceutical research. 2010; vol.9, no.2, pmcid: pmc3862056. pmid: 24363715. Page no 107–114.
26. Abd El Gawad h, Solimano, et al. Formulation and evaluation of gel forming ocular minitablets containing piroxicam. British journal of pharmaceutical research. 2012; vol.2, no. 3. Doi:10.9734/bjpr/2012/1653. Page no141–167
27. W. Weyenberg, a. Vermeire, et al, “Effects of roller compaction settings on the preparation of bio adhesive granules and ocular minitablets, “European journal of pharmaceutics and biopharmaceutics, vol.59, no. 3. Doi: 10.1016/j.ejpb.2004.09.012 page no 527–536,
28. t. Loftsson, e. Stefansson, et al. “Cyclodextrins in eye drop ´formulations: enhanced topical delivery of corticosteroids to the eye,” acta ophthalmological Scandinavica, vol. 80, no. 2, . Https://doi.org/10.1034/j.1600-0420.2002.800205.x page no 144–150, 2002.
29. “The international pharmacopoeia,” 4th edition, 2013,http://apps.who.int/phint/en/p/abou
30. B. K. Nanjwade, d. B. Sonaje, et al. “preparation and evaluation of eye-drops for the treatment of bacterial conjunct tivitis,” ijpi’s journal of pharmaceutics and cosmetology, vol. 1, no. 2, page no 43–49, 2011.
31. S. Nagargoje, A. Phatak, et al. “for emulation and evaluation of ophthalmic delivery of fluconazole from ion activated in situ gelling system,” der Pharmacia letter, vol. 4, no. 4, page no 1228–1235, 2012.
32. l. Budai, m. Hajdu, m. Budai et al., “gels and liposomes ´in optimized ocular drug delivery: studies on ciprofloxacin formulations,” international journal of pharmaceutics, vol. 343, no. 1-2, doi: 10.1016/j.ijpharm.2007.04.013. page no 34–40, 2007
33. T. F. Vandamme and l. Brock, et al. “poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide,” journal of controlled release, vol. 102, no. 1, .https://doi.org/10.1016/j.jconrel.2004.09.015 page no 23–38, 2005
34. H. J. Jung, m. Abou-jaoude, et al. “glaucoma therapy by extended release of timolol from nanoparticle loaded silicone-hydrogel contact lenses,” journal of controlled release, vol. 165, no. 1, page no 82–89, 2013.
35. T. K. Das, et al. “Protein particulate detection issues in biotherapeutics development-current status,” aps pharm SciTech, vol. 13, no. 2, doi: 10.1208/s12249-012-97934 page no 732–746, 2012
36. Marion dubald 1,2, Sandrine bourgeois 1,3, et al. Véronique andrieu ophthalmic drug delivery systems for ant biotherapy doi:10.3390/pharmaceutics10010010 www.mdpi.com.
37. Achouri d, Alhanout k, et al. Recent advances in ocular drug delivery. Drug dev ind pharm. 2013 nov;39(11):1599-617. Doi:10.3109/03639045.2012.736515. Epub 2012 nov 16. Pmid: 23153114.
38. Djamila achouri1,2,4, Kamel alhanout3,4,5, et al. Véronique andrieu drug development and industrial pharmacy, 2012; early online: 1–19 © 2012 Informa healthcare usa, inc. doi: 10.3109/03639045.2012.736515.
39. Colin e Willoughby md, PhD, et al. free access anatomy and physiology of the human eye: effects of mucopolysaccharidoses disease on structure and function. Clinical & experimental ophthalmology volume 38, issue s1 https://doi.org/10.1111/j.1442-9071.2010.02363.
40. Mca vs.et al. The eye and visual nervous system: anatomy, physiology and toxicology. Environmental health perspectives, doi: 10.1289/ehp.82441 1982; 44: page no1-8
41. 1tahura.s. Sayed, 2dr. Iffath rizwana, et al. A review on quality analysis and evaluation of ophthalmic products 2021 jetir September 2021, volume 8, issue 9 www.jetir.org .
42. M. H. Aburahma, a. A. Mahmoud, et al. “Biodegradable ocular inserts for sustained delivery of brimonidine tartarate: preparation and in vitro/in vivo evaluation,” aaps pharm SciTech, vol.12, no. 4, Doi: 10.1208/s12249-011-9701-3 page no 1335–1347, 2011
43. International conference on harmonization, “stability testing of new drug substances and products q1a (r2),” federal register, vol. 68, no. 225, page no 65717–65718, 2003.
44. B. R. Matthews and g. M. Wall, et al. “Stability storage and testing of ophthalmic products for global registration,” drug development and industrial pharmacy, vol. 26, no. 12, page no 122712
45. Noomwong p, Ratana Sak w, et al. Development of acyclovir-loaded bovine serum albumin nanoparticles for ocular drug delivery. International journal of drug delivery. 2011;3(4): page no 669–675.
46. Prajapati pa, Patel mm, et al. Formulation and in vitro evaluation of atropine sulphate viscous ocular solutions for the mydriatic and cycloplegic effect. International journal of pharmaceutical and applied sciences. 2010;1(2): page no 70–78.
47. Mundada as, Shrikhande bk, et al. Design and evaluation of soluble ocular drug insert for controlled release of ciprofloxacin hydrochloride. Drug development and industrial pharmacy. 2006;32(4): pmid: 16638682 doi: 10.1080/03639040500534101 pmid: 16638682: page no 443–448
48. Sadek Ahmed, Maha M. Amin, et al., Ocular Drug Delivery: a Comprehensive Review, / Published by- AAPS PharmSciTech (2023), https://doi.org/10.1208/s12249-023-02516-9, Page no. 1-29
49. Chrominfo: Advantages and disadvantages of ocular route of drug administration
50. Dale E, Fajardo, et al. American academy of ophthalmology 2009. Ophthalmic Case Study 1 | Ophthalmology and Visual Sciences | Medical College of Wisconsin (mcw.edu)
51. Azari AA, Barney NP. Conjunctivitis: A systematic review of diagnosis and treatment. JAMA. 2013;310(16):1721–9
52. Rajat Maheshwari, Ezekiel Weis, et al. Thyroid associated orbitopathy. Indian ophthalmol 2022 Mar-Apr 60(2) page no: 87-93. Doi: 10.4103/0301-4738.94048.